Rigetti Computing, Inc. RGTI
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Mar 7, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
11 paragraphs in Risk Factors of the 10-K filed Mar 4, 2026 with nothing like them in the 10-K filed Mar 7, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
We believe that our existing balances of cash, cash equivalents and available-for-sale investments will be sufficient to meet our anticipated operating cash needs for at least the next twelve months based on our current business plan, and expectations and assumptions considering current macroeconomic conditions. Our operating plan may change because of factors currently unknown, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations or other transactions. For example, in the future, we may seek to significantly increase our capital expenditures, including to upgrade our chip fabrication facility, possibly invest in a new quantum chip fabrication facility and for additional quantum computing refrigerators, which would require a significant amount of cash for capital expenditures.
We face significant technical and engineering challenges in completing the development of our quantum computers, producing our quantum computers at scale, achieving our targeted performance milestones, and realizing quantum advantage or LFTQC, any of which if not accomplished would adversely impact our business, financial condition, and results of operations.
In addition, our perceived relationship with the U.S. government could adversely affect our business prospects in certain non-U.S. geographies or with certain non-U.S. governments.
Changes in the government’s attitude towards the capabilities that we offer, or us as a company or our platforms;
Our ability to compete successfully depends on continuous innovation, timely execution of our strategy, and achieving cost reductions and failure to do so could render our quantum computing systems obsolete or less competitive.
Show the other 6
Even if we successfully develop our quantum computing solution and executing our strategy, customer preferences may change, or competitors may achieve technological breakthroughs in science, physics, or manufacturing that render our technology obsolete or inferior. While it is uncertain whether such breakthroughs will occur in the near term, they may occur eventually, and any such advancement could materially impact our business, financial condition or results of operations.
Our operating results could be below the expectations of public market analysts and investors due to a number of potential factors, including: our ability to meet our technological milestones (in a timely fashion or at all); changes in the industries in which we and our customers operate; the relative performance of our competitors; adverse impacts of global military conflicts and wars; anticipated or actual fluctuations in our operating results; publication of research reports by securities analysts about us or our competitors or our industry; rumors and market speculation involving us or our competitors, which may include short seller reports; the public’s reaction to our press releases, public announcements and filings with the SEC; our or our competitors’ failure to meet analyst projections or guidance; additions and departures of key personnel; changes in laws or regulations affecting our business, including accounting standards, policies, guidelines, interpretations and principles; involvement in litigation involving the Company, or actions by institutional or activist stockholders; future sales or issuances of our securities; the volume of our securities available for public sale or resale; and other events or factors, including recessions, increases in inflation and interest rates, disruptions to banking systems, foreign currency fluctuations, international tariffs, social, political and economic risks, natural disasters, acts of war (including the conflict involving Russia and Ukraine), terrorism or responses to such events. These market and industry factors may materially reduce the market price of our Common Stock and our Public Warrants regardless of the operating performance of the Company. In the past, following periods of market volatility, stockholders have instituted securities class action litigation. If we are involved in securities litigation, it could have a substantial cost and divert resources and the attention of executive management from our business regardless of the outcome of such litigation.
On May 29, 2025, we filed an automatic shelf registration statement on Form S-3ASR with the SEC, which enables us to offer for sale, from time to time, an unspecified amount of Common Stock, preferred stock, debt securities and warrants. The Form S-3ASR became automatically effective upon filing and is valid for three years.
Under the current rules of the SEC, we will no longer be eligible to take advantage of the scaled disclosures available to smaller reporting companies beginning with our Quarterly Report on Form 10-Q for the first quarter of 2026. We expect that the loss of the ability to take advantage of scaled disclosures will result in increased legal, accounting and financial compliance costs.
During the year ended December 31, 2025, 4,830,235 shares were issued upon the exercise of warrants. The additional shares issued resulted in dilution to the holders of Common Stock and increased the number of shares outstanding. To the extent additional warrants are exercised, stockholders may experience additional dilution. Sales of substantial shares in the public market or the fact that warrants have been and may continue to be exercised could adversely affect the market price of our Common Stock.
We have the ability to redeem outstanding Public Warrants prior to their expiration, at a redemption price of $0.01 per warrant, provided that the last reported sales price of our Common Stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which we provide notice of redemption and certain other conditions are met. In such event, holders may exercise their warrants prior to the scheduled redemption date, but only for cash, and the market price of our Common Stock may decline below both the $18.00 redemption threshold and the $11.50 exercise price following the issuance of the redemption notice.
Paragraphs in the 10-Q filed Nov 10, 2026 that were not in the one before
New in the latest 10-Q
36 paragraphs in the 10-Q filed Nov 10, 2026 with nothing like them in the 10-Q filed Aug 6, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
10-Q
the ability to satisfy the funding conditions of, and to realize the anticipated benefits from, the transaction with the U.S. Department of Commerce (the “Department”), and the impact of the restrictions and requirements under the transaction agreements on our business,
Read in the 10-Q
Financial statements and notes
On September 8, 2026, in connection with the Company’s agreements with the U.S. Department of Commerce under the U.S. CHIPS Act of 2022, the Company issued 7,739,938 shares of Common Stock. See Note 16, “U.S. Department of Commerce CHIPS Act Award,” for additional information regarding this issuance and the related accounting.
Read in the 10-Q
During the nine months ended September 30, 2025, the Company raised gross proceeds of $350 million from the sale of 30,309,780 shares of its Common Stock pursuant to the Sales Agreement, at a weighted average price of $11.55 per share, which represented the full amount of shares available for sale under the Sales Agreement. The net proceeds from the Sales Agreement during the nine months ended September 30, 2025 were $346.7 million, after deducting Agent commissions totaling $3.3 million. As of September 30, 2026, there were no remaining shares available for sale pursuant to the Sales Agreement.
Read in the 10-Q
In 2013, the Company adopted the 2013 Equity Incentive Plan (the “2013 Plan”) which provided for the grant of qualified incentive stock options (“ISOs”) and nonqualified stock options (“NSOs”), restricted stock, restricted stock units (“RSUs”) or other awards to the Company’s employees, officers, directors, advisors, and outside consultants. After the Business Combination became effective on March 2, 2022, no additional awards were issued under the 2013 Plan. Awards outstanding under the 2013 Plan continue to be governed by such plan; however, the Company will not grant any further awards under the 2013 Plan.
Read in the 10-Q
The Company has not been public for a sufficient length of time to derive expected volatility solely from trading in its Common Stock. The expected term of stock options granted was calculated using the simplified method, which represents the average of the contractual term and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical exercise data for its options to provide a reasonable basis upon which to estimate the expected term. The assumed dividend yield was based upon the Company’s expectation of not paying dividends in the foreseeable future. The risk-free rate was based upon the U.S. Treasury yield curve in effect at the time of grant for the period equivalent to the expected term of the stock option. In determining the exercise prices for stock options granted, the Company’s board of directors has utilized the fair value of the Common Stock as of the grant date. Before the Business Combination, the fair value of the Common Stock had been determined by the board of directors at each award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company’s financial position and historical financial performance, the status of technological developments within the Company, the composition and ability of the current engineering and management team, an evaluation or benchmark of the Company’s competition, the current business climate in the marketplace, the illiquid nature of the Company’s Common Stock, arm’s-length sales of the Company’s capital stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event, among others. The valuation assumptions used as inputs to the Black-Scholes option-pricing model to value stock options granted during the nine months ended September 30, 2026, were as follows: Valuation Assumptions Time-based Stock Option Grants Strike price $16.99 Annual volatility (%) 120% Risk- free rate (%) 3.81% Expected term (years) 5.77 RSUs The following is a summary of RSU activity: Weighted Average Grant Date Fair Shares Value Non-vested at December 31, 2025 7,333,182 $ 7.15 Granted 4,181,650 17.17 Vested (2,834,339) 5.53 Forfeited (187,627) 10.30 Non-vested at September 30, 2026 8,492,866 $ 12.56 As of September 30, 2026, the Company’s non-vested RSUs have a service-based vesting condition ranging from 1-4 years. During the year ended December 31, 2023, the Company granted 3,850,000 RSUs with a market-based vesting condition tied to the Company’s stock price. Based upon the terms of such awards, 50% of the shares became vested when the Company’s Common Stock traded at or above $2.00 per share and the other 50% of the shares became vested when the Company’s Common Stock traded at or above $4.00 per share, for 20 out of 30 trading days through the fifth anniversary of the grant date. The $2.00 per share vesting condition was satisfied in December 2024, and the $ 4.00 per share vesting condition was satisfied in January 2025. The income tax withholding obligation for all RSUs are satisfied through the sale of shares into the market, otherwise known as Sell-To-Cover (“STC”). The STC transaction and the income tax withholding remittance for the market-based RSUs that vested in December 2024 took place on December 30, 2024. The $6.3 million proceeds from the STC were received by the Company on January 2, 2025. The weighted-average grant date fair value of RSUs granted during the nine months ended September 30, 2026 and September 30, 2025, was $17.17 and $13.78 per share, respectively. The aggregate fair value of outstanding RSUs based on the closing share price of the Company’s Common Stock as of September 30, 2026 and September 30, 2025, was $133.7 million and $250.6 million, respectively. The aggregate fair value of RSUs that vested based on the closing price of the Company’s Common Stock on the vesting date during the nine months ended September 30, 2026 and September 30, 2025 was $48.2 million and $69.0 million, respectively.
Read in the 10-Q
Show the other 31
The Company capitalizes deferred contract fulfillment costs that relate directly to a contract, generate or enhance resources that will be used to satisfy future performance obligations, and are expected to be recovered. These costs primarily consist of direct implementation, setup, and onboarding activities performed while fulfilling a customer contract. These capitalized contract fulfillment costs are amortized on a systematic basis that is consistent with the transfer to the customer of the corresponding goods or services.
Read in the 10-Q
As of September 30, 2026, capitalized contract fulfillment costs related to a future system delivery were approximately $4.8 million. The Company had no capitalized contract fulfillment costs as of December 31, 2025. No amortization or impairment charges for capitalized contract fulfillment costs were recognized during the three or nine months ended September 30, 2026 or the three and nine months ended September 30, 2025.
Read in the 10-Q
(11) Segments, Geographical Information, Concentrations and Significant Customers
Read in the 10-Q
In addition to consolidated net loss, the Company’s Chief Operating Decision Maker (the Chief Executive Officer) reviews and utilizes natural expenses such as employee wages and benefits at a consolidated level to manage the Company’s operations and strategic growth initiatives. The measure of segment assets is reported in the balance sheet as total consolidated assets. The following table sets forth our
Read in the 10-Q
(1)Other segment items include interest income, changes in fair value of derivative warrant liabilities and earnout liabilities and other operational expenses which are reflected in the condensed consolidated statements of operations.
Read in the 10-Q
Revenues from external customers are attributed to individual countries based on the physical location in which the services are provided or the particular customer location with whom the Company has contracted.
Read in the 10-Q
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and trade accounts receivable. The Company’s cash and cash equivalents are placed with high-credit-quality financial institutions, and at times exceed federally insured limits. To date, the Company has not experienced any credit loss relating to its cash and cash equivalents.
Read in the 10-Q
During the three and nine months ended September 30, 2026, sales to government entities comprised 81.5% and 30.0% of the Company’s total revenue, respectively. During the three and nine months ended September 30, 2025, sales to government entities comprised 92.6% and 91.4% of the Company’s total revenue, respectively.
Read in the 10-Q
On September 4, 2026 (the “Award Date”), the Company’s wholly-owned subsidiary, Rigetti & Co, LLC, entered into an Other Transaction Agreement (the “Other Transaction Agreement”) with the U.S. Department of Commerce (the “Department”) under the U.S. CHIPS Act of 2022 (the “CHIPS Act”), pursuant to which the Department agreed to provide the Company with funding in the amount of up to $100 million (the “Award”) to accelerate superconducting quantum computing research and development. The Other Transaction Agreement contemplates that the Company will pursue research and development activities related to three overall project tasks to address key technical challenges related to superconducting quantum computing: (i) compressing readout electronics into an integrated, miniaturized package, (ii) expanding cryogenic capacity by orders of magnitude using a new cryostat architecture, and (iii) developing the fabrication capabilities for high-connectivity chip architectures.
Read in the 10-Q
The Other Transaction Agreement commenced on the Award Date and terminates on the earlier of (i) the date all of the milestones under the Other Transaction Agreement have been completed or (ii) the fifth anniversary of the Award Date, unless earlier terminated in accordance with the terms set forth in the Other Transaction Agreement (the “Period of Performance”). The Company may request an amendment of the Other Transaction Agreement to extend the Period of Performance by submitting a request to the Department at least sixty calendar days prior to the expiration of the Period of Performance.
Read in the 10-Q
Under the Other Transaction Agreement, $43.9 million of the Award was made available to the Company on the Award Date, and two subsequent tranches of $29.9 million and $26.2 million will be made available by the Department to the Company if the Department determines to its satisfaction that the Company has achieved the milestones with respect to the respective tranche in accordance with the applicable success criteria and by the applicable milestone date for such tranche. The Department has sole discretion to determine whether milestones have been satisfactorily achieved. The Other Transaction Agreement allows the Company to withdraw available funds under the Award to pay for eligible project costs, which must be expended within 30 days of withdrawal. If the Company fails to complete any required project activity under the Other Transaction Agreement prior to the applicable required project activity date, subject to any applicable cure period and/or forbearance provisions, the Department may demand recovery of the aggregate amount of payments made to the Company pursuant to the Other Transaction Agreement.
Read in the 10-Q
The Other Transaction Agreement provides the Department with the right to demand recovery of the aggregate amount of payments made to the Company for material non-compliance with security and domestic control and production requirements therein. In addition, the Department has the right to terminate the Other Transaction Agreement if there is a material failure to comply with the security and domestic control and production provisions, or any other provision of the Other Transaction Agreement determined by the Department to be material.
Read in the 10-Q
The Department may terminate the Other Transaction Agreement for convenience by providing sixty-days’ written notice. If the Company has completed each of the required project activities, it may terminate the Period of Performance for convenience by providing sixty-days’ prior written notice to the Department. If the Other Transaction Agreement is terminated for convenience by the Department prior to the latest required project activity date, the rights of the Department to demand recovery of the aggregate amount of payments made to the Company pursuant to the Other Transaction Agreement will also terminate.
Read in the 10-Q
As inducement for the Department to enter into the Other Transaction Agreement, on September 8, 2026, the Company entered into a Securities Issuance Agreement (the “Securities Issuance Agreement”) with the Department pursuant to which 7,739,938 shares of the Company’s Common Stock (the “Shares”) were issued to the Department at an implied issuance price of $12.92 per Share. Among other items, the Securities Issuance Agreement provides for: (i) a restriction on merger or consolidation, or sale, transfer or lease of all or substantially all of the Company’s property or assets, unless the successor, transferee or lessee party (other than the Company) expressly assumes the obligations of the Company under the Securities Issuance Agreement, (ii) a limitation on the number of Shares that the Department can transfer without prior written consent of the Company to the number of Shares equivalent to the amounts disbursed (and not returned) under the Award, (iii) a prohibition on transfers in a privately negotiated transaction to any competitor of
Read in the 10-Q
the Company, (iv) certain resale shelf registration rights and piggyback registration rights in favor of the Department, (v) a covenant that the Department will not vote any Shares, except with respect to (A) certain matters that would or would have the effect of increasing or decreasing the aggregate number of authorized shares of Common Stock, increasing or decreasing the par value of the Common Stock, or altering or changing the powers, preferences, or special rights of the Common Stock so as to adversely affect the Common Stock and (B) any merger, consolidation or similar business combination involving the Company, and (vi) in the event the Department terminates the Other Transaction Agreement, the Company will have the right to repurchase from the Department, at an aggregate purchase price of $1.00, that number of Shares equivalent to the amount of the Award that had not been disbursed or returned. The Securities Purchase Agreement contains customary representations and warranties of the Company.
Read in the 10-Q
The Company concluded that: (i) the research funding received from the Department under the Other Transaction Agreement is government assistance outside the scope of ASC 606, ASC 730-20, and ASC 912-730, and would be accounted for by analogy to International Accounting Standard (“IAS”) 20 and ASC 958 given the lack of authoritative guidance on government grants to for-profit entities; (ii) the 7,739,938 shares of Common Stock issued to the Department as inducement to enter into the Other Transaction Agreement are freestanding equity instruments classified as permanent equity; and (iii) because the issuance-date fair value of the Shares (approximately $122.4 million) exceeds the full $100.0 million of award consideration, a residual allocation of proceeds results in the entire $100.0 million being allocated to the Shares. Accordingly, eligible project costs will continue to be capitalized or expensed under normal U.S. GAAP, and no residual grant income or reduction of the related project costs will be recognized. At issuance, the Company recorded the legal issuance of the Shares at par value, with an offsetting debit to additional paid-in capital, resulting in no net increase in stockholders’ equity. As amounts under the Award are subsequently withdrawn for eligible project costs, the Company will recognize the cash funding received with a corresponding credit to additional paid-in capital when retention of the funding is probable. If retention is not probable because the funding remains subject to potential recovery under the Other Transaction Agreement, the amount withdrawn will instead be recognized as a liability until the repayment contingency is resolved.
Read in the 10-Q
As of September 30, 2026: (1) the Company concluded that receipt of the Award is probable, (2) no amounts had been received and cumulative amounts expended to date under the Award were insignificant.
Read in the 10-Q
On September 4, 2026 (the “Award Date”), our wholly-owned subsidiary, Rigetti & Co, LLC (“Rigetti Sub”), entered into an Other Transaction Agreement (the “Other Transaction Agreement”) with the U.S. Department of Commerce (the “Department”) under the U.S. CHIPS Act of 2022 (the “CHIPS Act”), pursuant to which the Department agreed to provide us with funding in the amount of up to $100 million (the “Award”) to accelerate superconducting quantum computing research and development. The Other Transaction Agreement contemplates that we will pursue research and development activities related to three overall project tasks to address key technical challenges related to superconducting quantum computing: (i) compressing readout electronics into an integrated, miniaturized package, (ii) expanding cryogenic capacity by orders of magnitude using a new cryostat architecture, and (iii) developing the fabrication capabilities for high-connectivity chip architectures.
Read in the 10-Q
The Other Transaction Agreement commenced on the Award Date and terminates on the earlier of (i) the date all of the milestones under the Other Transaction Agreement have been completed or (ii) the fifth anniversary of the Award Date, unless earlier terminated in accordance with the terms set forth in the Other Transaction Agreement (the “Period of Performance”). We may request an amendment of the Other Transaction Agreement to extend the Period of Performance by submitting a request to the Department at least sixty calendar days prior to the expiration of the Period of Performance.
Read in the 10-Q
Under the Other Transaction Agreement, $43.9 million of the Award was made available to us on the Award Date, and two subsequent tranches of $29.9 million and $26.2 million will be made available by the Department to us if the Department determines to its satisfaction that we have achieved the milestones with respect to the respective tranche in accordance with the applicable success criteria and by the applicable milestone date for such tranche. The Department has sole discretion to determine whether milestones have been satisfactorily achieved. The Other Transaction Agreement allows us to withdraw available funds under the Award to pay for eligible project costs, which must be expended within 30 days of withdrawal. If we fail to complete any required project activity under the Other Transaction Agreement prior to the applicable required project activity date, subject to any applicable cure period and/or forbearance provisions, the Department may demand recovery of the aggregate amount of payments made to us pursuant to the Other Transaction Agreement.
Read in the 10-Q
As inducement for the Department to enter into the Other Transaction Agreement, on September 8, 2026, we entered into a Securities Issuance Agreement (the “Securities Issuance Agreement”) with the Department pursuant to which 7,739,938 shares of our common stock (the “Shares”) were issued to the Department at an implied issuance price of $12.92 per share. In the event the Department terminates the Other Transaction Agreement, we will have the right to repurchase from the Department, at an aggregate purchase price of $1.00, that number of Shares equivalent to the amount of the Award that had not been disbursed or returned.
Read in the 10-Q
We concluded that (i) the research funding received from the Department under the Other Transaction Agreement is government assistance outside the scope of ASC 606, ASC 730-20, and ASC 912-730, and would be accounted for by analogy to IAS 20 and ASC 958 given the lack of authoritative guidance on government grants to for-profit entities; (ii) the 7,739,938 shares of common stock issued to the Department as inducement to enter into the Other Transaction Agreement are freestanding equity instruments classified as permanent equity; and (iii) because the issuance-date fair value of the shares (approximately $122.4 million) exceeds the full $100.0 million of award consideration, a residual allocation of proceeds results in the entire $100.0 million being allocated to the shares. Accordingly, eligible project costs will continue to be capitalized or expensed under normal U.S. GAAP, and no residual grant income or reduction of the related project costs will be recognized.
Read in the 10-Q
Comparison of the Three and Nine Months Ended September 30, 2026 and September 30, 2025
Read in the 10-Q
Risk Factors
The Other Transaction Agreement contains restrictions relating to foreign entities and national security that may limit our business activities and strategic flexibility.
Read in the 10-Q
Under the Other Transaction Agreement Documents, during the Period of Performance and for five years following the Period of Performance, we are subject to significant restrictions relating to foreign entities and national security. Among other things, we may not materially expand business operations or establish new business operations in a Foreign Country of Concern (i.e., China) without the Department’s written approval. We may not acquire, take any ownership interest in, invest in, or engage in joint ventures with a Foreign Entity of Concern without such approval. We may not knowingly solicit or receive, directly or indirectly, any investment from any Foreign Entity of Concern, including in connection with debt and equity financing activities, without the Department’s written approval, subject to a limited carve-out for purchases of publicly traded securities by a Foreign Entity of Concern on secondary markets without our knowledge or approval. We may not engage in research partnerships or technology transfers of developed technologies with Foreign Entities of Concern without written approval from the Department. We may not provide, or enter into commercial agreements to provide, any services or products to a Foreign Entity of Concern without such approval. In addition, we are required to not knowingly permit or facilitate the acquisition by any Foreign Entity of Concern of direct or indirect beneficial ownership of more than a specified percentage of the voting equity interests in us or our parent company. These restrictions could limit our ability to pursue international partnerships, investments, or business opportunities and could adversely affect our competitive position in markets where foreign entities play a significant role.
Read in the 10-Q
The U.S. Government has certain rights in intellectual property and data developed under the Other Transaction Agreement, including march-in rights, which could limit our ability to fully commercialize funded innovations.
Read in the 10-Q
Under the Other Transaction Agreement, the U.S. Government has a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on behalf of the United States any Subject Inventions (as defined in the Other Transaction Agreement) developed under the agreement throughout the world for government purposes. In addition, the Department has march-in rights that allow it to require us, our assignees, or exclusive licensees to grant non-exclusive licenses to responsible applicants upon reasonable terms if, among other things, we have not taken, or are not using good faith efforts to take, effective steps to achieve practical application of a Subject Invention, or if such action is necessary to alleviate public health or national security needs not reasonably satisfied by us. Additionally, we have granted the U.S. Government a license to use certain project background intellectual property to the extent embedded in or necessary for the exercise of rights in Subject Inventions. These government rights could limit our ability to exclusively commercialize innovations developed with government funding, and the exercise of march-in rights could result in competitors gaining access to our technology on commercially reasonable terms, which could adversely affect our competitive position and the value of our intellectual property.
Read in the 10-Q
The Other Transaction Agreement imposes extensive compliance, reporting, and certification obligations that will require administrative resources and could expose us to penalties for non-compliance.
Read in the 10-Q
The Other Transaction Agreement imposes a wide range of compliance, reporting, and certification obligations on us. Among other things, we are required to comply with the Davis-Bacon Act prevailing wage requirements, Executive Order requirements, including certifications regarding anti-discrimination compliance, and cybersecurity reporting obligations. We must also maintain a Research Security Plan (as defined in the Other Transaction Agreement) that includes restrictions on research partnerships with Foreign Countries and Entities of Concern, and we must obtain the Department’s approval of our Covered Individual List (as defined in the Other Transaction Agreement) before engaging in research and development activities. We are subject to semiannual financial reporting, annual technical milestone status reports, patent reports, annual research security plan certifications, and annual third-party information technology security assessments. Any failure to comply with these obligations could trigger remedies available to the Department, including withholding of payments, recovery of disbursed funds, suspension or debarment, or termination of the Other Transaction Agreement, any of which could have a material adverse effect on our business, prospects, financial condition, or results of operations.
Read in the 10-Q
Given the limited number of precedents for transactions of this type, it is difficult to foresee all the potential consequences. There could be adverse reactions, immediately or over time, from investors, employees, customers, suppliers, other business or commercial partners, foreign governments or competitors, as well as increased public or political scrutiny of the Company, and there may also be litigation relating to the transactions. Furthermore, the Department’s status as a stockholder may subject us to additional regulations or restrictions, could create uncertainty for potential investors or business partners, and could limit our ability to secure future government grants or incentives from other governmental entities, whether domestic or foreign, or cause other governmental entities to seek similar equity arrangements as a condition of providing support. Competitors may view the government’s equity interest in us as creating an actual or potential organizational conflict of interest and challenge contract awards based on alleged organizational conflicts of interest, potentially resulting in bid protests, corrective action, delays in performance, or the cancellation or modification of an award. Unless potential or actual conflicts can be mitigated, neutralized or avoided, an organizational conflict of interest may prohibit us from competing for or performing certain contracts, require divestiture or the discontinuation of existing contract work, or otherwise restrict business activities. These restrictions and proceedings could reduce our addressable market, delay or prevent anticipated revenue, increase costs, and materially adversely affect our business, financial condition, and results of operations.
Read in the 10-Q
Share sales and buybacks
No sales or issuances of unregistered securities occurred that have not previously been disclosed in a Current Report on Form 8-K
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 10, 2026 against Item 1A of the 10-K filed Mar 4, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
What the 10-Q itself says about its risk factors:In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K Risk Factors”) for a more complete understanding of the risks and uncertainties material to our business that make an investment in our securities speculative or risky. There have been no material changes to our risk factors as previously disclosed in the 2025 Form 10-K Risk Factors, except as follows:
Read in the 10-Q
Show the other 8
The first 13 of 20 are shown (at most 12 of each type).
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed Mar 4, 2026 that are in none of the 1 earlier 10-Ks stored, back to Mar 7, 2025
Where each one is used
- fabrication facility: Our business and future plans for expansion are capital-intensive, and the specific timing of cash inflows and outflows may fluctuate substantially from period to period. We will require a significant amount of cash for expenditures as we invest in ongoing research and development and business operations. For...
- chip fabrication: Our business and future plans for expansion are capital-intensive, and the specific timing of cash inflows and outflows may fluctuate substantially from period to period. We will require a significant amount of cash for expenditures as we invest in ongoing research and development and business operations. For...
- fidelity based: Our business was founded in 2013 and has operated quantum computers over the cloud since 2017. As a result of our limited operating history, our ability to accurately forecast the future results of operations is limited and subject to a number of uncertainties, including our ability to plan for and model future...
- possibly invest: Our business and future plans for expansion are capital-intensive, and the specific timing of cash inflows and outflows may fluctuate substantially from period to period. We will require a significant amount of cash for expenditures as we invest in ongoing research and development and business operations. For...
- new quantum: Our business and future plans for expansion are capital-intensive, and the specific timing of cash inflows and outflows may fluctuate substantially from period to period. We will require a significant amount of cash for expenditures as we invest in ongoing research and development and business operations. For...
- quantum chip: Our business and future plans for expansion are capital-intensive, and the specific timing of cash inflows and outflows may fluctuate substantially from period to period. We will require a significant amount of cash for expenditures as we invest in ongoing research and development and business operations. For...
- new fabrication: Our failure to manage growth effectively could harm our business, results of operations and financial condition. We anticipate that a period of significant expansion will be required to address potential growth. This expansion will place a significant strain on our management, operational and financial resources....
- expected develops: In addition, the market for quantum computers is still rapidly evolving, characterized by rapidly changing technologies, competitive pricing and competitive factors, evolving government regulation and industry standards, and changing customer demands and behaviors. If the market for quantum computers in general...
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
What was taken out
91 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RGTI/export.csv") into a cell.